• SPX
  • $5,969.34
  • 0.35 %
  • $20.63
  • DJI
  • $44,296.51
  • 0.97 %
  • $426.16
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $19,003.65
  • 0.16 %
  • $31.23
Adverum Biotechnologies, Inc. (ADVM) Stock Price, News & Analysis

Adverum Biotechnologies, Inc. (ADVM) Stock Price, News & Analysis

Currency in USD Disclaimer

$6.05

$0.3

(5.22%)

Day's range
$5.69
Day's range
$6.15
50-day range
$5.69
Day's range
$8.56
  • Country: US
  • ISIN: US00773U1088
52 wk range
$5.69
Day's range
$29.7


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -5.85
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (ADVM)
  • Company Adverum Biotechnologies, Inc.
  • Price $6.05
  • Changes Percentage (5.22%)
  • Change $0.3
  • Day Low $5.69
  • Day High $6.15
  • Year High $29.70

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/17/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $15.00
  • High Stock Price Target $28.00
  • Low Stock Price Target $2.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$10.20
  • Trailing P/E Ratio -0.72
  • Forward P/E Ratio -0.72
  • P/E Growth -0.72
  • Net Income $-117,165,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Adverum Biotechnologies, Inc. Frequently Asked Questions

  • What is the Adverum Biotechnologies, Inc. stock price today?

    Today's price of Adverum Biotechnologies, Inc. is $6.05 — it has increased by +5.22% in the past 24 hours. Watch Adverum Biotechnologies, Inc. stock price performance more closely on the chart.

  • Does Adverum Biotechnologies, Inc. release reports?

    Yes, you can track Adverum Biotechnologies, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Adverum Biotechnologies, Inc. stock forecast?

    Watch the Adverum Biotechnologies, Inc. chart and read a more detailed Adverum Biotechnologies, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Adverum Biotechnologies, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Adverum Biotechnologies, Inc. stock ticker.

  • How to buy Adverum Biotechnologies, Inc. stocks?

    Like other stocks, ADVM shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Adverum Biotechnologies, Inc.'s EBITDA?

    Adverum Biotechnologies, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Adverum Biotechnologies, Inc.’s financial statements.

  • What is the Adverum Biotechnologies, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -32.5458333333, which equates to approximately -3,254.58%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Adverum Biotechnologies, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Adverum Biotechnologies, Inc.'s financials relevant news, and technical analysis. Adverum Biotechnologies, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Adverum Biotechnologies, Inc. stock currently indicates a “sell” signal. For more insights, review Adverum Biotechnologies, Inc.’s technical analysis.

  • A revenue figure for Adverum Biotechnologies, Inc. for its last quarter?

    Adverum Biotechnologies, Inc. published it's last quarterly revenues at $1.00 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.